Once a DMT is initiated, evidence suggests that treatment needs to be ongoing for benefits to persist. Non-adherence and gaps in treatment have been associated with an increased rate of […]

As mentioned earlier in this booklet, healthcare professionals and organizations including MSAA recommend early and continuous treatment of multiple sclerosis through FDA-approved DMTs, if deemed appropriate by one’s doctor. However, […]

This easy-to-follow reference chart shows those medications that have been approved by the FDA and are available for the long-term treatment of relapsing forms of MS. This chart does not […]

While the issue of treatment adherence continues to gain awareness and momentum, MSAA also recognizes the complexity of the situation. Healthcare providers continue to encourage their patients to become more […]

The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by the United States Food and Drug Administration (FDA) in 1993. This forever changed the landscape of how MS could […]

MSAA’s S.E.A.R.C.H.™ program is just one of several programs designed as tools for individuals with MS and their families to play a more active role in the successful management of […]